Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Prostatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Squamous Cell Carcinoma of Head and Neck 5Breast Neoplasms 5Head and Neck Neoplasms 4Lung Neoplasms 3Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Osteosarcoma 2Oropharyngeal Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Mouth Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Adenocarcinoma 2Wilms Tumor 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomatitis 1Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 1Squamous Cell Cancer of Head and Neck (SCCHN) 1Skin Neoplasms 1Sarcoma, Clear Cell 1Rhabdoid Tumor 1Recurrence 1

Interventions

Cisplatin 55Carboplatin 50pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Cetuximab 18Docetaxel 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 13Sorafenib 12Radiation 11130-nm albumin-bound paclitaxel 11Sunitinib 10Platinum 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × Radiotherapy, Image-Guided × Clear all
NCT06532279 2026-05-04

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NRG Oncology

Phase 2 Recruiting
98 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Stomatitis

NCT06084845 2024-07-25

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡